- Ritter Pharmaceuticals - http://www.ritterpharmaceuticals.com -

Andrew Ritter Named Finalist for 2nd Consecutive Year in LA Business Journal’s Annual Healthcare Leadership Awards

LOS ANGELES, Calif., May 5, 2014 — Andrew Ritter, president and CEO of Ritter Pharmaceuticals, Inc., was selected as a finalist for the second consecutive year in the fourth annual Healthcare Leadership Awards presented by The Los Angeles Business Journal.  Over the past year, Andrew has positioned Ritter Pharmaceuticals at the forefront of human gut microbiome research by exploring the metabolic capacity of gut microbiota and translating the functionality of prebiotic therapeutics into safe and effective applications. Ritter Pharma’s lead product, RP-G28, is being developed to treat lactose intolerance.

The LA Business Journal honored their award recipients and finalists at a banquet on Wednesday, April 23 and featured them in a special supplement to the publication, released on April 28.  Andrew was recognized in the Research Executive category for his focus on lactose intolerance and other conditions that may be treated by microbiome modulation such a Crohn’s disease, inflammatory bowel disease, and neurological and cardiovascular diseases.

“I am once again thankful to be considered a healthcare leader in Los Angeles by the Los Angeles Business Journal’s Awards committee,” said Andrew Ritter.  “I also want to congratulate the other award winners for their contributions to the local community and helping society live healthier lives.”

Ritter Pharmaceuticals

Ritter Pharmaceuticals, Inc. develops novel therapeutic products, which modulate the human gut microbiome to treat inflammatory, gastrointestinal and metabolic diseases.  Ritter Pharma’s microbiome modulators provide specialized nutrition that selectively increases the growth of beneficial bacteria in the colonic ecosystem and creates significant improvement in the health of individuals that suffer from these diseases. Ritter Pharma’s RP-G28 is the first investigational drug candidate to complete a Phase 2 clinical study for lactose intolerance.